Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-05-05 4:37 pm Purchase |
2023-05-03 | 13G | TCR2 Therapeutics Inc. TCRR |
TANG CAPITAL PARTNERS LP | 4,215,864 10.700% |
1,476,917 (+53.92%) |
Filing History |
| 2023-05-05 4:34 pm Sale |
2023-05-03 | 13D | Jounce Therapeutics, Inc. JNCE |
TANG CAPITAL PARTNERS LP | 10,000 100.000% |
-5,290,087 (-99.81%) |
Filing History |
| 2023-05-01 4:00 pm Purchase |
2023-04-20 | 13G | MEI Pharma, Inc. MEIP |
TANG CAPITAL PARTNERS LP | 361,084 5.400% |
361,084 (New Position) |
Filing History |
| 2023-05-01 4:00 pm Purchase |
2023-04-20 | 13G | Genfit S.A. GNFT |
TANG CAPITAL PARTNERS LP | 2,643,147 5.300% |
2,643,147 (New Position) |
Filing History |
| 2023-04-20 4:13 pm Purchase |
2023-04-10 | 13G | Bolt Biotherapeutics, Inc. BOLT |
TANG CAPITAL PARTNERS LP | 2,732,250 7.200% |
2,732,250 (New Position) |
Filing History |
| 2023-04-17 4:00 pm Purchase |
2023-04-05 | 13G | InflaRx N.V. IFRX |
TANG CAPITAL PARTNERS LP | 3,000,000 5.500% |
3,000,000 (New Position) |
Filing History |
| 2023-04-07 4:00 pm Unchanged |
2023-04-05 | 13D | Jounce Therapeutics, Inc. JNCE |
TANG CAPITAL PARTNERS LP | 5,300,087 10.200% |
0 (Unchanged) |
Filing History |
| 2023-03-31 4:00 pm Purchase |
2023-03-21 | 13G | Quince Therapeutics, Inc. QNCX |
TANG CAPITAL PARTNERS LP | 3,620,000 9.980% |
3,620,000 (New Position) |
Filing History |
| 2023-03-28 4:00 pm Unchanged |
2023-03-26 | 13D | Jounce Therapeutics, Inc. JNCE |
TANG CAPITAL PARTNERS LP | 5,300,087 10.200% |
0 (Unchanged) |
Filing History |
| 2023-03-17 4:00 pm Unchanged |
2023-03-17 | 13D | Jounce Therapeutics, Inc. JNCE |
TANG CAPITAL PARTNERS LP | 5,300,087 10.200% |
0 (Unchanged) |
Filing History |
| 2023-03-17 4:00 pm Purchase |
2023-03-07 | 13G | Bellerophon Therapeutics, Inc. BLPH |
TANG CAPITAL PARTNERS LP | 1,062,619 9.990% |
1,062,619 (New Position) |
Filing History |
| 2023-03-14 5:00 pm Purchase |
2023-03-14 | 13D | Jounce Therapeutics, Inc. JNCE |
TANG CAPITAL PARTNERS LP | 5,300,087 10.200% |
300,087 (+6.00%) |
Filing History |
| 2023-03-13 4:00 pm Purchase |
2023-03-03 | 13G | Adicet Bio, Inc. ACET |
TANG CAPITAL PARTNERS LP | 2,271,520 5.300% |
2,271,520 (New Position) |
Filing History |
| 2023-03-06 4:00 pm Purchase |
2023-02-23 | 13G | Jounce Therapeutics, Inc. JNCE |
TANG CAPITAL PARTNERS LP | 5,000,000 9.700% |
5,000,000 (New Position) |
Filing History |
| 2023-02-24 4:00 pm Purchase |
2023-02-14 | 13G | Elevation Oncology, Inc. ELEV |
TANG CAPITAL PARTNERS LP | 1,355,826 5.800% |
1,355,826 (New Position) |
Filing History |
| 2023-02-21 4:00 pm Purchase |
2023-02-10 | 13G | Evolus, Inc. EOLS |
TANG CAPITAL PARTNERS LP | 3,038,732 5.400% |
3,038,732 (New Position) |
Filing History |
| 2023-02-14 4:00 pm Sale |
2022-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS |
TANG CAPITAL PARTNERS LP | 0 0.000% |
-3,101,709 (Position Closed) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | CytomX Therapeutics, Inc. CTMX |
TANG CAPITAL PARTNERS LP | 3,510,445 5.300% |
39,545 (+1.14%) |
Filing History |
| 2023-02-14 4:00 pm Sale |
2022-12-31 | 13G | Heron Therapeutics, Inc. HRTX |
TANG CAPITAL PARTNERS LP | 3,756,694 3.200% |
-4,026,994 (-51.74%) |
Filing History |
| 2023-02-14 4:00 pm Unchanged |
2022-12-31 | 13G | Inspirato Incorporated ISPO |
TANG CAPITAL PARTNERS LP | 0 0.000% |
0 (Unchanged) |
Filing History |